Tata Memorial Hospital   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Mumbai India (1941)

Organization Overview

First Clinical Trial
1997
NCT00123669
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

ACTREC,Tata Memorial Centre | Department of Anaesthesia, Critical Care and Pain, Tata Memorial Hospital, parel, mumbai, India | Dr Rajendra A. Badwe | Professor and Medical Oncologist, Tata Memorial Hospital, Mumbai, India | Sudeep Gupta | Tata Main Hospital | Tata Main Hospital, Jamshedpur, India | Tata Medical Center | Tata Memorial Center | Tata Memorial Centre | Tata Memorial Centre Advanced Centre for Treatment, Research and Education in Cancer | Tata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital | Tata Memorial Hospital | Tata Memorial Hospital, Ernest Borges Road, Parel, Mumbai 400 012 | Tata Memorial Hospital, Mumbai | TATA MEMORIAL HOSPITAL , MUMBAI | Tata Memorial Hospital, Mumbai-400012,India | Tata Memorial Hospital, Mumbai-400012, India | Tata Memorial Hospital, Mumbai, India

Active Ingredients

Drugs in Phase 4 Trials (4)

dexmedetomidine (precedex) (2 trials)

granisetron (kytril) (1 trial)

human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant (Gardasil) (1 trial)

ondansetron (zofran) (1 trial)

Drugs in Phase 3 Trials (17)

carboplatin (paraplatin) (1 trial)

cisplatin (platinol) (4 trials)

conjugated equine estrogens (1 trial)

curcumin (3 trials)

eadm (1 trial)

gemcitabine (gemzar) (1 trial)

hydroxyprogesterone (Delalutin) (1 trial)

lidocaine (xylocaine) (1 trial)

nelfinavir (viracept) (1 trial)

paclitaxel (taxol) (2 trials)

progesterone (progestasert) (1 trial)

sorafenib (nexavar) (1 trial)

tamoxifen (nolvadex) (1 trial)

tranexamic acid (cyklokapron) (1 trial)

trastuzumab (herceptin) (1 trial)

vitamin d3 (1 trial)

zoledronic acid (zometa) (2 trials)

Drugs in Phase 2 Trials (11)

ashwagandha extract (1 trial)

bevacizumab (avastin) (1 trial)

celecoxib (celebrex) (1 trial)

epidermal growth factor (1 trial)

erlotinib (tarceva) (1 trial)

leflunomide (arava) (1 trial)

mt-102 (1 trial)

riviciclib (2 trials)

sodium copper chlorophyllin (1 trial)

thalidomide (Thalomid) (1 trial)

urea (1 trial)

Drugs in Phase 1 Trials (1)

talotrexin (1 trial)

Drugs in Other Trials (11)

atracurium (tracurium) (1 trial)

azithromycin (zithromax) (1 trial)

cefixime (suprax) (1 trial)

fentanyl (Innovar) (1 trial)

nitrous oxide (1 trial)

norepinephrine (levophed) (1 trial)

oxygen (1 trial)

propofol (diprivan) (1 trial)

ringer's lactate (1 trial)

ropivacaine (naropin) (1 trial)

sevoflurane (ultane) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Cachexia (Phase 2)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Squamous Cell (Phase 2)

Central Nervous System Neoplasms (Phase 1)

Cognitive Dysfunction (Phase 4)

Fibrosis (Phase 3)

Gallbladder Neoplasms (Phase 3)

Head and Neck Neoplasms (Phase 3)

Leukemia (Phase 1)

Liver Neoplasms (Phase 3)

Lymphoma (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 2)

Nervous System Neoplasms (Phase 1)

Osteosarcoma (Phase 3)

Pulmonary Fibrosis (Phase 3)

Tongue Neoplasms (Phase 2)

Triple Negative Breast Neoplasms (Phase 3)

Urinary Bladder Neoplasms (Phase 3)

Uterine Cervical Neoplasms (Phase 4)

Wasting Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 34
  • # of Trial APIs: 44